

Leo Mascarenhas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1336231/leo-mascarenhas-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114 papers	4,255 citations	26 h-index	64 g-index
125 ext. papers	5,558 ext. citations	4 avg, IF	4.9 L-index

#	Paper	IF	Citations
114	Independent Assessment of the Children's Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis.. <i>JAMA Network Open</i> , 2022 , 5, e2148013	10.4	1
113	Kaposiform hemangioendothelioma of the bone in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2022 , 69, e29392	3	0
112	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.. <i>Pediatric Blood and Cancer</i> , 2022 , e29644	3	1
111	Cutaneous mosaic RASopathies associated with rhabdomyosarcoma.. <i>Pediatric Blood and Cancer</i> , 2022 , e29639	3	0
110	Reply to J.-G. Wang et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102922	2.2	
109	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100358	2.2	8
108	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021 , 45, 100734	2.3	5
107	Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
106	Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS11577-TPS11577	2.2	1
105	Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11514-11514	2.2	1
104	Oral selpercatinib in pediatric patients (pts) with advanced RET-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10009-10009	2.2	0
103	Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Cancer</i> , 2021 , 127, 946-956	6.4	2
102	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28832	3	3
101	SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. <i>Cancer</i> , 2021 , 127, 1301-1310	6.4	9
100	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. <i>Cancer Medicine</i> , 2021 , 10, 843-856	4.8	1
99	Relapsed Rhabdomyosarcoma. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	6
98	Pediatric Metastatic Hepatoblastoma With an Mutation and Rhabdoid Cells. <i>International Journal of Surgical Pathology</i> , 2021 , 10668969211042638	1.2	0

97	Metabolic response as assessed by F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. <i>Cancer Medicine</i> , 2021 , 10, 857-866	4.8	8
96	Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2020 , 3, e2014205	10.4	10
95	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020 , 2020, 7935475	3.1	9
94	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology, The</i> , 2020 , 21, 531-540	21.7	279
93	Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3614-3614	2.2	2
92	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020 , 22, 785-796	1	10
91	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. <i>Oncologist</i> , 2020 , 25, e1655-e1662	5.7	5
90	Expanding the spectrum of dicer1-associated sarcomas. <i>Modern Pathology</i> , 2020 , 33, 164-174	9.8	30
89	Abnormal Pulmonary Lymphatic Flow in Patients With Lymphatic Anomalies and Respiratory Compromise. <i>Chest</i> , 2020 , 158, 681-691	5.3	6
88	Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2866-2874	2.2	30
87	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019 , 109, 36-50	7.5	180
86	Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2019 , 125, 2602-2609	6.4	11
85	Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 41-50	3.5	8
84	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1424-1431	2.2	93
83	A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with acute lymphoblastic leukemia (ALL): A COG ACCL1033 study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10007-10007	2.2	10007
82	Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10010-10010	2.2	6
81	Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6602-6602	2.2	3
80	A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS10066-TPS10066	2.2	2

79	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018 , 378, 731-739	59.2	1285
78	Three synchronous malignancies in a patient with DICER1 syndrome. <i>European Journal of Cancer</i> , 2018 , 93, 140-143	7.5	7
77	Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. <i>Lancet Oncology</i> , 2018 , 19, 705-714	21.7	280
76	Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy. <i>Pediatric and Developmental Pathology</i> , 2018 , 21, 480-485	2.2	2
75	Vincristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26728	3	19
74	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. <i>British Journal of Cancer</i> , 2018 , 119, 615-621	8.7	47
73	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11505-11505	2.2	2
72	Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10541-10541	2.2	1
71	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2770-2777	2.2	74
70	The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. <i>Cancer</i> , 2018 , 124, 4241-4247	6.4	75
69	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. <i>Blood</i> , 2017 , 129, 1919-1926	2.2	21
68	Inherited germline ATRX mutation in two brothers with ATR-X syndrome and osteosarcoma. <i>American Journal of Medical Genetics, Part A</i> , 2017 , 173, 1390-1395	2.5	21
67	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1730-1736	2.2	17
66	Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3688-3696	2.2	8
65	Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a single institution. <i>Histopathology</i> , 2017 , 71, 813-822	7.3	14
64	A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10510-10510	2.2	10
63	Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS10577-TPS10577	2.2	1
62	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10514-10514	2.2	1

61	A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2599-TPS2599	2.2	
60	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1396-1408	21.7	253
59	Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 493-8	3	21
58	18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10549-10549	2.2	8
57	A pediatric phase 1 study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS10583-TPS10583	2.2	2
56	Combined clinical and genetic risk prediction of central nervous system subsequent neoplasms (CNS SNs) in childhood cancer survivors (CCS): A report from the COG ALTE03N1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10511-10511	2.2	
55	Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. <i>Cancer Medicine</i> , 2016 , 5, 294-303	4.8	12
54	Is INI1-retained small cell undifferentiated histology in hepatoblastoma unfavorable?. <i>Human Pathology</i> , 2015 , 46, 620-4	3.7	11
53	Sarcomas. <i>Pediatric Clinics of North America</i> , 2015 , 62, 179-200	3.6	42
52	Correlation of pulmonary function abnormalities with dose volume histograms in children treated with lung irradiation. <i>Pediatric Pulmonology</i> , 2015 , 50, 596-603	3.5	4
51	Insulin-like Growth Factor 2 Gene Expression Molecularly Differentiates Pleuropulmonary Blastoma and Embryonal Rhabdomyosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2015 , 37, e356-60	1.2	1
50	Pilot Feasibility Study of Comprehensive Pulmonary Evaluation Following Lung Radiation Therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2015 , 37, e412-8	1.2	4
49	Hepatoblastoma in a patient with methylmalonic aciduria. <i>American Journal of Medical Genetics, Part A</i> , 2015 , 167A, 635-8	2.5	12
48	Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma. <i>Journal of Pediatric Hematology/Oncology</i> , 2015 , 37, e399-401	1.2	13
47	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>JAMA Oncology</i> , 2015 , 1, 287-95	13.4	84
46	Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. <i>Pediatric Hematology and Oncology</i> , 2015 , 32, 26-31	1.7	7
45	Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 756-9	3	19
44	Hepatoblastoma and hypoplastic kidneys: a new association. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 1476-8		4

43	Nuclear protein in testis midline carcinoma misdiagnosed as adamantinoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, e57-60	2.2	9
42	High dose alkylator therapy for extracranial malignant rhabdoid tumors in children. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 1357-61	3	24
41	Successful treatment of recurrent metastatic nasopharyngeal carcinoma with oxaliplatin and doxorubicin. <i>Journal of Pediatric Hematology/Oncology</i> , 2014 , 36, e307-9	1.2	2
40	Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. <i>Clinical Cancer Research</i> , 2014 , 20, 6314-23	12.9	48
39	Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 1679-84	3	26
38	Hepatoblastoma in a 15-month-old female with trisomy 13. <i>American Journal of Medical Genetics, Part A</i> , 2014 , 164A, 472-5	2.5	3
37	Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1109-14	4	10
36	Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. <i>Pediatric Blood and Cancer</i> , 2014 , 61, 1277-81	3	17
35	De novo congenital melanoma: analysis of 2 cases with array comparative genomic hybridization. <i>American Journal of Dermatopathology</i> , 2014 , 36, 915-9	0.9	11
34	Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10003-10003	2.2	23
33	Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10004-10004	2.2	16
32	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) study AALL03N1.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10013-10013	2.2	2
31	Orthopaedic case of the month: A 14-year-old boy with a medial thigh soft tissue mass. <i>Clinical Orthopaedics and Related Research</i> , 2013 , 471, 1433-8	2.2	1
30	A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. <i>Pediatric Blood and Cancer</i> , 2013 , 60, 1103-7	3	12
29	Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 942-8	4	21
28	Ewing sarcoma of the tibia mimicking fibrous dysplasia. <i>Journal of Pediatric Orthopaedics Part B</i> , 2013 , 22, 222-7	1.4	3
27	Inflammatory myofibroblastic tumors in childhood. <i>Pediatric Hematology and Oncology</i> , 2013 , 30, 640-5	1.7	21
26	A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. <i>PLoS ONE</i> , 2013 , 8, e68416	3.7	31

25	A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS10591-TPS10591	2.2	1
24	Comprehensive profiling of cardiac dysfunction in asymptomatic childhood cancer survivors (CCS) treated with anthracyclines.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10020-10020	2.2	
23	Correlation of long-term pulmonary injury with radiation dose distribution in childhood cancer survivors. <i>Practical Radiation Oncology</i> , 2012 , 2, 237-240	2.8	0
22	Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. <i>Pediatric Blood and Cancer</i> , 2012 , 59, 493-8	3	24
21	Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2094-101	2.2	218
20	Pleuropulmonary blastoma: a single-institution experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2012 , 34, e182-5	1.2	10
19	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse In Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2012 , 120, 882-882	2.2	2
18	Effect of insulin-like growth factor 2 gene expression on pleuropulmonary blastoma and embryonal rhabdomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 9564-9564	2.2	
17	Gorham's disease and diffuse lymphangiomatosis in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 667-70	3	36
16	Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011 , 57, 939-42	3	27
15	Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011 , 1, 61-3	2.2	4
14	Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4658-63	2.2	70
13	Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. <i>Journal of Bone and Joint Surgery - Series A</i> , 2009 , 91, 604-12	5.6	32
12	Recurrent and refractory giant cell tumor of the jaw. <i>Journal of Craniofacial Surgery</i> , 2009 , 20, 2245-8	1.2	3
11	Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2008 , 51, 334-8	3	139
10	Extracranial malignant rhabdoid tumors in childhood: the Childrens Hospital Los Angeles experience. <i>Cancer</i> , 2007 , 110, 2061-6	6.4	53
9	Treatment of infantile choriocarcinoma of the liver. <i>Pediatric Blood and Cancer</i> , 2007 , 49, 99-102	3	21
8	Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2007 , 48, 165-72	3	20

7	Invasive diagnostic procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant recipients. <i>Pediatric Transplantation</i> , 2007 , 11, 736-42	1.8	10
6	Severe methotrexate toxicity precipitated by intravenous radiographic contrast. <i>Journal of Pediatric Hematology/Oncology</i> , 2007 , 29, 496-9	1.2	8
5	Extended mutational analyses of FGFR1 in osteoglophonic dysplasia. <i>American Journal of Medical Genetics, Part A</i> , 2006 , 140, 537-9	2.5	38
4	Transient myeloproliferative disorder in a phenotypically normal infant with i(21q) mosaicism. <i>Cancer Genetics and Cytogenetics</i> , 2002 , 136, 138-40		7
3	Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. <i>Blood</i> , 2000 , 96, 1317-1326	2.2	88
2	Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 1998 , 92, 3537-3545	2.2	32
1	Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 1998 , 92, 3537-3545	2.2	12